Capaian Pembelajaran
Mahasiswa mampu menjelaskan:
1. CKD konsep umum
2. Pathophysiology (etiology, pato-mechanism,
clinical manifestation)
3. Nursing care; pengkajian, masalah
keperawatan, & intervensi keperawatan
1
25/09/2017
CKD
Progressive & Irreversible
loss of kidney function
Leading causes:
Disbetes
Hipertension
2
25/09/2017
Pato-mechanism
Pato-Mechanism
3
25/09/2017
.Pato-mechanism
Other causes:
Systemic diseases; Lupus &
rheumatoid arthritis
Infection
Medication
Toxins
Clinical manifestations
Water
retention
4
25/09/2017
..Clinical manifestation
..Clinical manifestation
5
25/09/2017
Pato-Mechanism
https://www.youtube.com/watch?v=bwwQd7
xkHNc
https://www.youtube.com/watch?v=JjcqY95H
R1o
Modifiable Factors
Non-Modifiable Factors -Diabetic Mellitus
-Hereditary -Hypertension
-Age greater than 60 years old -Increase Protein and
-Gender Cholesterol Intake
-Race -Smoking
-Use of analgesics
Hypertrophy of
remaining nephrons
Dilute
Polyuria
Inability to Loss of Sodium in
Hyponatremia
concentrate urine Urine
Dehydration
Further loss of
nephron function
Loss of nonexcretory 2
renal function a
Advanced
Calcium Erratic blood
Anemia atherosclerosis Delayed Infection Libido Infertility
absorption glucose
Pallor levels wound
healing
1
6
25/09/2017
2
Hypocalcemia 1 a
Osteodystrophy
Loss of excretory renal
function
Hyperparathyroidism
Peripheral
nerve
Decreased potassium
changes
excretion
Pericarditis
Increased
potassium
CNS
changes
Pruritus
Altered Taste
Bleeding
Tendencies
Nursing Care
Assessment:
Chief complain; PQRST
Health History;
Reason admitted to Hospital
Adherence; diet, fluid intake, dyalisis,
etc
7
25/09/2017
Assessment:
Physical Exam;
General ;
consciousness,
edema,
IDWG
Vital signs,
Breathing sound
Calculate I O
Collaborative Care
Conservative therapy
Correction of extracellular fluid volume
overload or deficit
Nutritional therapy
Erythropoietin therapy
Calcium supplementation, phosphate binders
8
25/09/2017
Collaborative Care
Drug Therapy (contd)
Hyperkalemia (contd)
Sodium polystyrene sulfonate (Kayexalate)
Cation-exchange resin
Resin in bowel exchanges potassium for sodium
9
25/09/2017
Collaborative Care
Drug Therapy (contd)
Hyperkalemia (contd)
Sodium polystyrene sulfonate (Kayexalate) (contd)
Evacuates potassium-rich stool from body
Educate patient that diarrhea may occur due to laxative
in preparation
10
25/09/2017
Collaborative Care
Drug Therapy (contd)
Hypertension (contd)
Antihypertensive drugs
Diuretics
-Adrenergic blockers
Calcium channel blockers
Collaborative Care
Drug Therapy (contd)
Hypertension (contd)
Antihypertensive drugs (contd)
Angiotensin-converting enzyme (ACE) inhibitors
Angiotensin receptor blocker agents
11
25/09/2017
Collaborative Care
Drug Therapy (contd)
Renal osteodystrophy
Phosphate intake restricted to
<1000 mg/day
Collaborative Care
Drug Therapy (contd)
Renal osteodystrophy (contd)
Phosphate binders
Calcium carbonate (Tums)
Bind phosphate in bowel and excreted
Sevelamer hydrochloride (Renagel)
Lowers cholesterol and LDLs
12
25/09/2017
Collaborative Care
Drug Therapy (contd)
Renal osteodystrophy (contd)
Phosphate binders (contd)
Should be administered with each meal
Side effect: Constipation
Collaborative Care
Drug Therapy (contd)
Renal osteodystrophy (contd)
Supplementing vitamin D
Calcitriol (Rocaltrol)
Serum phosphate level must be lowered before
administering calcium or vitamin D
13
25/09/2017
Collaborative Care
Drug Therapy (contd)
Renal osteodystrophy (contd)
Controlling secondary hyperparathyroidism
Calcimimetic agents
Cinacalcet (Sensipar)
SensiNvity of calcium receptors in parathyroid glands
Subtotal parathyroidectomy
14
25/09/2017
Collaborative Care
Drug Therapy (contd)
Anemia (contd)
Iron supplements
If plasma ferritin <100 ng/ml
Side effect: Gastric irritation,
constipation
May make stool dark in color
Collaborative Care
Drug Therapy (contd)
Anemia (contd)
Folic acid supplements
Needed for RBC formation
Removed by dialysis
Avoid blood transfusions
15
25/09/2017
Collaborative Care
Drug Therapy (contd)
Dyslipidemia (contd)
Fibrates
Fibric acid derivatives
Most effective for lowering triglycerides
Can also decrease HDLs
16
25/09/2017
17
25/09/2017
Collaborative Care
Nutritional Therapy (contd)
Potassium restriction
2 to 4 g
High-potassium foods should be avoided
Oranges
Bananas
Tomatoes
Green vegetables
18
25/09/2017
Collaborative Care
Nutritional Therapy (contd)
Phosphate restriction
1000 mg/day
Foods high in phosphate
Dairy products
Most foods high in phosphate are also high in
calcium
Collaborative
Dyalisis; HD/PD
https://www.youtube.com/watch?v=mi34xCfmL
hw
19
25/09/2017
Nursing Management
Nursing Assessment
Complete history of any existing renal disease,
family history
Long-term health problems
Dietary habits
Nursing Management
Nursing Diagnoses
Excess fluid volume
Risk for injury
Imbalanced nutrition: Less than body
requirements
Grieving
Risk for infection
20
25/09/2017
Nursing Management
Planning
Overall goals
Demonstrate knowledge and ability to comply
with therapeutic regimen
Participate in decision making
Demonstrate effective coping strategies
Nursing Management
Planning
Overall goals (contd)
Continue with activities of daily living within
psychologic limitations
21
25/09/2017
Nursing Management
Nursing Implementation
Health promotion
Identify individuals at risk for CKD
History of renal disease
Hypertension
Diabetes mellitus
Repeated urinary tract infection
Regular checkups and changes in urinary
appearance, frequency, and volume should be
reported
Nursing Management
Nursing Implementation (Contd)
Acute intervention
Daily weight
Daily BPs
Identify signs and symptoms of fluid overload
Identify signs and symptoms of hyperkalemia
Strict dietary adherence
22
25/09/2017
Nursing Management
Nursing Implementation (Contd)
Acute intervention (contd)
Medication education
Motivate patients in management of their disease
Nursing Management
Nursing Implementation (Contd)
Ambulatory and home care
When conservative therapy is no longer effective,
HD, PD, and transplantation are treatment options
Patient/family need clear explanation of dialysis
and transplantation
23
25/09/2017
Nursing Management
Evaluation
Maintenance of ideal body weight
Acceptance of chronic disease
No infections
No edema
Hematocrit, hemoglobin, and serum albumin
levels in acceptable range
24